Why the study?
Do PGI2-analogues and NO donors inhibit the expression of adhesion molecules on activated platelets, and does this effect differ in diabetic patients?
Do PGI2-analogues and NO donors inhibit the expression of adhesion molecules on activated platelets, and does this effect differ in diabetic patients?
Platelets from type 1 diabetic patients exhibit partial resistance to the inhibitory effects of PGI2-analogues on thrombogenic adhesion molecule expression, likely due to a post-adenylate cyclase defect.
No takes yet. Share an insight, caveat, or question.
May signal reduced PGI2 analogue efficacy in type 1 diabetes; hypothesis-generating and leaves open dose optimization trials.
Rösen et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: